Can We Define High-risk DAPT Patients in USA Practice? - Roxana Mehran, MD, FACC, FSCAI

↳ This is a section part of Moment: CRT 2016 Technology & Innovation - Evaluating DES for High-risk DAPT Patients

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$3.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Can We Define High-risk DAPT Patients in USA Practice? presented by Roxana Mehran, MD, FACC, FSCAI at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$3.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Clinical Trial Investigators
  • Interventional Fellows
  • Medical Device Professionals


Session Name: Evaluating DES for High-risk DAPT Patients

Track: Technology & Innovation

Learning Objectives

  • Updates in the latest Cardiovascular Innovations

Other Components in this Moment

Overview
Adjunctive DAPT Labelling for DES - an FDA View - Andrew Farb, MD
Can We Define High-risk DAPT Patients in USA Practice? - Roxana Mehran, MD, FACC, FSCAI
The Long and Short of DAPT – an Industry View - Craig Thompson, MD, FSCAI
Loading Simple Education